Maritide vs Zepbound
Which Is Right for You? Complete Comparison (2026)
MariTide vs Zepbound comparison — Amgen monthly GLP-1/GIPR antibody vs Eli Lilly weekly tirzepatide peptide, GIPR antagonism vs agonism debate.
Maritide vs Zepbound: At a Glance
- ✓Bispecific: GIP receptor antagonist + GLP-1 receptor agonist
- ✓Opposite mechanism to tirzepatide (which is dual agonist)
- ✓Monthly dosing (long half-life antibody component)
- ✓Phase 2 showed ~15% weight loss at 12 weeks
- ✓Developed by Amgen
- ✓Dual GIP + GLP-1 receptor agonist — first in class
- ✓GIP agonism enhances insulin sensitivity in adipose tissue
- ✓~21% mean weight loss at 72 weeks (SURMOUNT-1, 15 mg)
- ✓GIP may moderate GI side effects vs GLP-1-only drugs
- ✓Half-life ~5 days — once-weekly injection
Detailed Comparison
| Feature | Maritide | Zepbound |
|---|---|---|
| Mechanism | Bispecific GIP antagonist / GLP-1 agonist | Dual GIP/GLP-1 receptor agonistBest |
| Dosing | Monthly SC injection (phase 2) | 2.5-15 mg SC weekly |
| Administration | Subcutaneous injection monthly | Subcutaneous injection weekly |
| Half-life | Long — antibody-based (monthly dosing) | ~5 days |
| FDA Status | Not FDA-approved — phase 2 clinical trials | FDA-approved: Mounjaro (T2D), Zepbound (obesity) |
| Key Trial | Mather KJ et al. Obesity 2024 — phase 2 results | Jastreboff AM et al. NEJM 2022 (SURMOUNT-1) — 20.9% weight loss |
| Side Effects | Nausea, vomiting, diarrhea | Nausea (31%), vomiting, diarrhea, constipation |
Which Should You Choose?
Maritide (AMG 133) (bispecific gip antagonist / glp-1 agonist) and Tirzepatide (dual gip/glp-1 receptor agonist) serve different clinical roles despite both being in the Bispecific anti-obesity space. Maritide (AMG 133) novel bispecific antibody-peptide that blocks gip receptor while activating glp-1 receptor — opposite approach to tirzepatide which activates both. Tirzepatide first-in-class dual gip and glp-1 receptor agonist that activates two incretin pathways for enhanced weight loss and glycemic control vs single agonists.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Maritide and Zepbound
Choosing between Maritide and Zepbound depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Maritide and Zepbound is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Maritide vs Zepbound: Frequently Asked Questions
Maritide (AMG 133) is a bispecific gip antagonist / glp-1 agonist while Tirzepatide is a dual gip/glp-1 receptor agonist. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Maritide (AMG 133) works as a bispecific gip antagonist / glp-1 agonist (Monthly SC injection (phase 2)), while Tirzepatide is a dual gip/glp-1 receptor agonist (2.5-15 mg SC weekly). They have different half-lives (Long — antibody-based (monthly dosing) vs ~5 days), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Maritide or Zepbound in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.